SCHEMBL4464115

SCHEMBL4464115

NS(=O)(=O)c1ccc(NC(=O)CNc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 12/20 0.68
CA2 P00918 12/20 0.68
CA12 O43570 7/20 0.68
CA7 P43166 2/20 0.68
CA9 Q16790 7/20 0.67
CA14 Q9ULX7 2/20 0.67
CA5A P35218 1/20 0.67
CA5B Q9Y2D0 1/20 0.67
TSHR P16473 1/20 0.63
MGLL Q99685 1/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
CA4 P22748 1/20 0.61
PTPN7 P35236 1/20 0.60
MAPT P10636 1/20 0.60
ERCC1 P07992 1/20 0.60
ERCC4 Q92889 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18361652 0.87 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL18361691 0.87 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL18649278 0.84 CA2 (0.65) CA1CA2CA12CA7CA9
SCHEMBL18361655 0.84 ALDH1A1 (0.60) CA1CA2CA12CA7CA9
SCHEMBL1561387 0.83 MAPT (0.70) TSHRMGLLMEN1KMT2AMAPT
SCHEMBL18361656 0.83 CA1 (0.73) CA1CA2CA12CA7CA9
SCHEMBL18361649 0.82 CA1 (0.70) CA1CA2CA12CA7CA9
Hydrochloric Acid SCHEMBL11858514 0.82 MAPT (0.68) TSHRMGLLMEN1KMT2AMAPT
SCHEMBL18361737 0.81 CA1 (0.70) CA1CA2CA12CA7CA9
SCHEMBL18361676 0.81 CA1 (0.61) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625917-B2 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein TURPIN JAMES A 2009-12-01 US disclosed
EP-1087941-B1 THIOLESTERS AND USES THEREOF US HEALTH (US) 2006-08-16 EP disclosed
US-20040132785-A1 Thiolesters and uses thereof The Government of the U. S.of America as Represented by The Sec. of Health and Human Svc. (US) 2004-07-08 US disclosed
US-6706729-B1 A METHOD FOR DISSOCIATING A METAL ION FROM A ZINC FINGER-CONTAINING PROTEIN; INHIBITING VIRUS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2004-03-16 US disclosed
EP-1087941-A2 THIOLESTERS AND USES THEREOF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 2001-04-04 EP disclosed
WO-1999065871-A2 THIOLESTERS AND USES THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132785-A1 Thiolesters and uses thereof SARS1, HAVCR2, P4HB CA1 3728/4885CA2 4550/4885CA12 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.